Skip to content Skip to sidebar Skip to footer
Tirzepatide improves heart health and function in obese HFpEF patients

Tirzepatide improves heart health and function in obese HFpEF patients

In the international SUMMIT trial, adults with heart failure preserved ejection fraction (HFpEF) and obesity taking tirzepatide for up to 3 years had a reduced combined risk of worsening heart failure events and cardiovascular death, and improved health status and physical function in comparison to participants taking placebo, according to late-breaking science presented today at…

Read more

the Kick-ass Multipurpose WordPress Theme

© 2025 Kicker. All Rights Reserved.